Mitochondria, Metabolism and Heart Failure

**Scientific Organizers:** 

Richard N. Kitsis | Gerald W. Dorn II | Rong Tian

Sponsored by:

**Bayer HealthCare Pharmaceuticals** 

**Takeda Pharmaceutical Company Limited** 

Supported by an educational donation provided by: Amgen

joint with

# Diabetes and Metabolic Dysfunction

Scientific Organizers:

Jeffrey E. Pessin | Alan R. Saltiel | Deborah M. Muoio

Sponsored by:

Intercept Pharmaceuticals, Inc.

Journal of Molecular Cell Biology (JMCB)

MedImmune

Novo Nordisk A/S

Pfizer Inc.

Supported by an educational donation provided by: Amgen

January 27–February 1, 2015
Santa Fe Community Convention Center
Santa Fe, New Mexico, USA



Accelerating Life Science Discovery



Accelerating Life Science Discovery

# Get Connected at the Meeting with our Mobile App!

### With the app you can:

- · Read speaker and poster abstracts
- · Send messages to other participants
- View other participants' profiles and photos
- See the up-to-date program and create a personalized agenda
- · Receive on-site announcements from our staff
- Take session-specific notes and email them to yourself
- "Favorite" sessions and abstracts you don't want to miss
- Find information about local-area activities, discounts and services

The app can be used via your smartphone, laptop or tablet browser. You can download it ahead of time for offline access without a wifi connection. To access the app for your meeting and upload your photo and profile, visit the link on page 3.

Keystone Symposia would like to thank BioLegend for sponsoring our 2014–2015 season mobile app. Please see the inside back cover of this book for a message from BioLegend.





## Poster Session 3: Friday, January 30

# J6 3010 Remodeling of Target Organ in Patients with Essential Hypertension in Combination with Obesity and Diabetes

<sup>1</sup><u>Shalimova A.S.</u>, <sup>1</sup>Kochueva M.N., <sup>2</sup>Belovol A.N., <sup>3</sup>Psareva V.G. and <sup>3</sup>Kirichenko N.N. <sup>1</sup>Kharkiv Medical Academy of Postgraduate Education, Ukraine, <sup>2</sup>Kharkiv National Medical University, Ukraine, <sup>3</sup>Sumy State University, Ukraine

Combination of essential hypertension (EH), type 2 diabetes mellitus (DM2) and obesity is associated with increased risk of cardiovascular events. Remodelling of target organs in hypertensive patients with combined pathology remains poorly investigated. The aim of the study was a comparative study of the structural and functional state of heart, vessels and liver in patients with isolated EH and in terms of its combination with DM2 or obesity. We examined 158 patients aged from 40 to 55 years old: 30 hypertensive patients without DM2 with normal body weight; 35 hypertensive patients with DM2 and normal body weight; 35 hypertensive patients without DM2 with overweight or obesity 1 degree; 38 hypertensive patients with DM2, overweight or obesity 1 degree; 20 almost healthy patients with body mass index (BMI) 18-24.9 kg/m<sup>2</sup>. The patients in all these groups had a saved ejection fraction of the left ventricle (LV). Not depending on BMI the patients with EH and DM2 in the comparison with hypertensive patients had different values of thickness of the intima-media in the carotid arteries (which were significantly higher), different pulse wave velocity in the great vessels, the size of the cavities and myocardial mass of the LV, the integral index of diastolic filling - E/e (integral ratio of maximum speeds of early diastolic filling according to spectral and tissue Doppler studies), the index of rigidity of the liver parenchyma according to shift-wave elastography and significantly lower value of endothelium-dependent vasodilatation of the brachial artery (p<0,05). Even a slight increase in BMI (not higher than 34.9 kg/m<sup>2</sup>) was associated with a deterioration of endothelial function and structural and functional properties of heart, blood vessels, liver, which is more pronounced in terms of comorbidity.